The adenosine A2A receptor as an attractive target for Parkinson's disease treatment

被引:29
作者
Chen, JF [1 ]
机构
[1] Boston Univ, Sch Med, Dept Neurol, Mol Neuropharmacol Lab, Boston, MA 02118 USA
关键词
D O I
10.1358/dnp.2003.16.9.829342
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Long-term L-dopa treatment of Parkinson's disease can lose its effectiveness and cause development of motor complications such as dyskinesia. Furthermore, L-dopa therapy does not address the fundamental pathological process of dopaminergic neurodegeneration in Parkinson's disease. This prompts a search for an alternative or complementary therapy for Parkinson's disease to overcome these limitations. During the last 5 years, the adenosine A(2A) receptor has emerged as an attractive target for Parkinson's disease therapy, primarily because of its localized expression in striatum and motor enhancement function. Recent genetic and pharmacological studies indicate that A(2A) receptor antagonists also offer neuroprotective effects and may possibly modify chronic L-dopa-induced maladaptive responses in animal models of Parkinson's disease. This review summarizes multiple potential benefits of the A(2A) receptor blockade in treating the motor symptoms as well as the underlying dopaminergic neurodegeneration of Parkinson's disease. (C) 2003 Prous Science. All rights reserved.
引用
收藏
页码:597 / 604
页数:8
相关论文
共 82 条
  • [1] BIOCHEMISTRY OF PARKINSONS-DISEASE 28 YEARS LATER - A CRITICAL-REVIEW
    AGID, Y
    CERVERA, P
    HIRSCH, E
    JAVOYAGID, F
    LEHERICY, S
    RAISMAN, R
    RUBERG, M
    [J]. MOVEMENT DISORDERS, 1989, 4 : S126 - S144
  • [2] Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist
    Aoyama, S
    Kase, H
    Borrelli, E
    [J]. JOURNAL OF NEUROSCIENCE, 2000, 20 (15) : 5848 - 5852
  • [3] Caffeine, postmenopausal estrogen, and risk of Parkinson's disease
    Ascherio, A
    Chen, H
    Schwarzschild, MA
    Zhang, SM
    Colditz, GA
    Speizer, FE
    [J]. NEUROLOGY, 2003, 60 (05) : 790 - 795
  • [4] Prospective study of caffeine consumption and risk of Parkinson's disease in men and women
    Ascherio, A
    Zhang, SMM
    Hernán, MA
    Kawachi, I
    Colditz, GA
    Speizer, FE
    Willett, WC
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (01) : 56 - 63
  • [5] ROLE OF ADENOSINE A(2A) RECEPTORS IN THE NUCLEUS-ACCUMBENS
    BARRACO, RA
    MARTENS, KA
    PARIZON, M
    NORMILE, HJ
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1994, 18 (03) : 545 - 553
  • [6] ADENOSINE A2A-RECEPTORS IN THE NUCLEUS-ACCUMBENS MEDIATE LOCOMOTOR DEPRESSION
    BARRACO, RA
    MARTENS, KA
    PARIZON, M
    NORMILE, HJ
    [J]. BRAIN RESEARCH BULLETIN, 1993, 31 (3-4) : 397 - 404
  • [7] Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
    Bezard, E
    Brotchie, JM
    Gross, CE
    [J]. NATURE REVIEWS NEUROSCIENCE, 2001, 2 (08) : 577 - 588
  • [8] BIBBIANI F, 2002, ANN M SOC NEUR ORL F
  • [9] Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats
    Bové, J
    Marin, C
    Bonastre, M
    Tolosa, E
    [J]. SYNAPSE, 2002, 46 (04) : 251 - 257
  • [10] Chase TN, 2001, ADV NEUROL, V86, P355